Skip to main content

Table 3 Incidence rate and median survival time of initial regimen change per groups of variables among children in public health facilities of Bahir Dar city, Northwest Ethiopia, 2021(N = 459)

From: Incidence and predictors of initial antiretroviral therapy regimen change among children in public health facilities of Bahir Dar City, Northwest Ethiopia, 2021: multicenter retrospective follow-up study

Variables

Categories

IR of IRC per 100 PMO

Median (IQR)

Sex

Male

1.95(1.68, 2.26)

46(37, 52)

Female

1.75(1.48, 2.06)

52(45, 57)

History tuberculosis

Yes

2.48(1.82, 3.36)

34(17, 52)

No

1.78(1.59 2.01)

50(45, 54)

Adherence

Good

1.66(1.46,1.90)

57(46, 56)

Poor/fair

2.57(2.09, 3.15)

37(25, 47)

ART drug regimen

ABC/3TC/EFV

1.89(1.05,3.41)

43(19, 60)

AZT/3TC/EFV

1.37(1.07, 1.73)

54(50, 64)

AZT/3TC/NVP

1.79(1.49, 2.14)

57(53, 59)

TDF/3TC/EFV

1.68(1.12, 2.50)

47(33, 56)

ABC/3TC/NVP

2.11(1.14, 3.93)

25(18, 46)

D4T/3TC/NVP

3.39(2.64, 4.36)

22(13,33)

D4T/3TC/EFV

3.26(2.02, 5.24)

17(13, 28)

  1. Hint ABC-abacavir, ART antiretroviral therapy, AZT zidovudine, 3TC lamuvidine, D4T stavudine, DTG Dolutegravir, EFV Efavirenz, IR Incidence rate, LPVr Lopinavir, NVP Nevirapine, TDF tenofavir disoproxil fumarate, IRC initial regimen change